In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

In a press release issued after market hours on February 20, Cipla announced that it has received approval for Nilotinib ...

The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

For Cipla Ltd, the market expert suggested the ... Singh also liked Sun Pharmaceutical Industries Ltd from the pharma segment. "The counter looked good on charts. One can buy the stock with ...

During the year, the Generics Business Undertaking of the Company was transferred to Cipla Pharma and Life Sciences Limited (CPLS), wholly owned subsidiary, on a slump sale basis as a going ...

Prior to joining Cipla, he was associated with Glenmark Pharmaceuticals as EVP Business Head EMEA L. Achin was a Member of the Core Operating Group, Director on the Board of key European affiliates ...

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Q3 Earnings, Results 2025: Companies like TVS Motor, Hindustan Zinc, Hyundai Motor, GMR Airports, Bajaj Auto, Cipla, Piramal Pharma, are releasing their Q3 numbers today. (Image: Freepik ...

Shares of drugmaker Cipla Ltd. surged to the day's high, gaining as much as 4% after the company's December quarter results. The results were a beat across parameters.

Cipla Ltd. has expressed optimism about exceeding its FY25 guidance, supported by strong operational performance and a focused strategy. The company stated that supply challenges related to Lanreotide ...